Introduction {#s1}
============

*SLC26A4* encodes an anion transporter transmembrane protein, pendrin, which is expressed in the thyroid, kidney, and cochlea [@pone.0049984-Everett1]. Pendrin is a member of the anion transporter family SLC26, which mediates the exchange of anions including Cl^-^, HCO~3~ ^-^, OH^-^, I^-^, or formate [@pone.0049984-Mount1]. In thyrocytes, iodide and sodium are brought into the cells via the basolaterally located sodium--iodide symporter. Apically located pendrin seems to be responsible for the efflux of iodide into the follicular lumen [@pone.0049984-Yoshida1]. In the kidney, pendrin is suspected to mediate Cl^−^/HCO~3~ ^-^ exchange in the acid--base regulating B- and non-A--non-B-intercalated cells [@pone.0049984-Kim1]. Similarly, in the inner ear, pendrin is thought to mediate Cl^−^/HCO~3~ ^-^ exchange, and is therefore involved in the conditioning of endolymphatic fluid, presumably due to HCO~3~ ^-^ secretion [@pone.0049984-Wangemann1]. Malfunction of pendrin leads to Pendred syndrome (PS) and non-syndromic DFNB4 deafness with EVA [@pone.0049984-Campbell1].

Pendred syndrome (PS) is the most common form of syndromic deafness and accounts for about 10% of hereditary hearing impairment [@pone.0049984-Reardon1]. It is an autosomal recessive disorder caused by biallelic mutations in *SLC26A4* resulting in hearing loss, enlargement of the vestibular aqueduct (EVA) and iodine organification defect in the thyroid gland [@pone.0049984-Pryor1]. EVA, diagnosed based on the criteria of a greater than 1.5-mm diameter at the midpoint between the common crus and the external aperture, is detected in the ears of patients with PS by computed tomography (CT) and magnetic resonance imaging (MRI) [@pone.0049984-Phelps1]. EVA is the most common form of inner ear malformations associated with prelingual or postlingual sensorineural hearing loss, and is an important feature of PS [@pone.0049984-Valvassori1]. EVA may occur alone or in combination with an incomplete partition of the apical turn of the cochlea as part of a Mondini deformity. PS is differentiated from non-syndromic hearing loss with EVA by the presence of goiter, which usually develops later at around the time of puberty. Since environmental and other genetic factors may modulate the effects of *SLC26A4* mutations on the development of goiter, the expression of goiter in PS patients is variable and may have incomplete penetrance [@pone.0049984-Park1]. Hearing loss in PS and DFNB4 occurs either congenitally or after some mild head injury, showing fluctuating and progressive hearing loss.

To-date, 174 *SLC26A4* mutations have been reported [@pone.0049984-Chang1]. The mutation spectrum varies widely among ethnic groups [@pone.0049984-Pryor1], [@pone.0049984-Park1], [@pone.0049984-Blons1]--[@pone.0049984-Wu1]. Park and Pryor observed that patients with PS were always associated with two mutant alleles in *SLC26A4*, consistent with autosomal recessive disorder, whereas patients with non-syndromic hearing loss and EVA might have one or no mutant allele [@pone.0049984-Pryor1], [@pone.0049984-Park1]. In a Caucasian non-syndromic EVA cohort, about one-third of the patients had two mutant alleles, one-third had one mutant allele and the remaining one-third had zero [@pone.0049984-Park1]. In Japanese and Korean, the proportions of EVA patients with two identified mutant alleles in *SLC26A4* are 57% and 81%, respectively [@pone.0049984-Park2], [@pone.0049984-Tsukamoto1]. In China, 97.9% of the EVA patients in simplex families were detected with either biallelic or monoallelic mutations, of which 88.4% carried biallelic variants and 9.5% had a monoallelic mutation. Only 2.1% of the Chinese patients with EVA had no mutant *SLC26A4* allele detected [@pone.0049984-Wang1].

*SLC26A4* mutations are the second-most common cause of deafness in China. The incidence of non-syndromic EVA accounts for 13.73% of hereditary hearing loss [@pone.0049984-Yuan1]. However, Pendred syndrome is relatively rare in the Chinese population. Molecular epidemiology surveys showed that there are more than 100 *SLC26A4* variants in the Chinese hearing loss population, of which at least half are novel. With genetic testing of deafness becoming more popular in China, verification of the pathogenicity of novel variants is essential for both genetic and prenatal diagnosis. However, the two parameters used thus far--(i) low incidence of the mutation in the control population and (ii) substitution of evolutionarily conserved amino acids by the mutation--are not sufficient for clinical genetic diagnosis. To investigate the incidence of EVA in Chinese hearing loss populations and provide appropriate genetic testing and counseling to patients with *SLC26A4* variants, we conducted a large-scale molecular epidemiological survey of *SLC26A4* in China. In addition, in order to assess the pathogenicity and understand the molecular mechanism(s) underlying EVA and hearing loss, we examined the membrane expression of pendrin and the transporter function of 10 variants that comprised six novel variants and four reported only in Chinese patients.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

A total of 2352 unrelated non-syndromic hearing loss patients from 27 different regions of China were included in this study. To sample as many regions of China as possible, we included the remote northwestern provinces, including Xinjiang (translates as 'New Territory'), Tibet, and Qinghai, where minorities make up a significant proportion of the local population. We also included samples from the southwestern provinces of Yunnan and Guizhou, where the populations comprise a number of minorities originating from various native tribes. The patients consisted of 1314 males and 1038 females ranging in age from 1.8 to 24 years with an average age of 14.17±3.41. The majority of patients were Han Chinese (1903), followed by minorities in the Southwest region (125), Tibetan (119), Hui (89), minorities in Xinjiang (69), Mongolian (33), Maan (12) and Korean (2). Ethnic subgroup designations were based on permanent residency documentation.

The subjects in this study were from special educational schools within each region. All patients showed moderate to profound bilateral sensorineural hearing impairment on audiograms. Careful medical examinations revealed no clinical features other than hearing impairment. In addition to the 2352 patients, 200 Han individuals with normal hearing (87 females and 113 males, aged 15 to 30 years) were recruited as control subjects from Beijing (Northern) and Jiangsu Province (Eastern), two densely populated regions consisting of 98 to 99% Han Chinese. Auditory function was evaluated by pure-tone air-and bone-conduction threshold audiometry.

Written informed consent was obtained from all subjects or guardians prior to blood sampling and genetic testing. The study protocol including the consent procedure was performed with the approval of the Ethics Committee of the Chinese PLA General Hospital.

Mutational Analysis of SLC26A4 {#s2b}
------------------------------

DNA was extracted from peripheral blood leukocytes using a commercially available DNA extraction kit (Watson Biotechnologies Inc., Shanghai, China). The open reading frame (ORF) of *SLC26A4* includes 2--20 exons. DNA sequence analyses of *SLC26A4* were performed by polymerase chain reaction (PCR) amplification of the coding exons plus approximately 50--100 bp of the flanking intron regions followed by Big Dye sequencing and analysis using an ABI 3100 DNA sequencing machine (ABI, Foster City, USA.) and ABI 3100 Analysis Software v.3.7 NT, according to the manufacturer's instructions. Because about 90% of Chinese EVA patients carried at least one allelic mutation in exons 8, 19 or 10 of *SLC26A4* [@pone.0049984-Wang1], [@pone.0049984-Dai1], [@pone.0049984-YuanYY1], we designated the three exons as hot spot regions and sequenced these first in all 2352 patients. For the patients with one allelic mutation or variant in exons 8, 19 or 10, the other exons of *SLC26A4* were sequenced one by one until two mutant alleles had been identified.

Normal-hearing controls were screened in exons 2--21 of *SLC26A4* for mutations or variants by DHPLC followed by sequencing analysis.

CT Scan and MRI {#s2c}
---------------

Patients with mutations or variants in *SLC26A4* were examined by temporal bone CT scan for diagnosis of inner ear malformation or EVA based on a diameter of \>1.5 mm at the midpoint between the common crus and the external aperture. Some patients with EVA were further examined using magnetic resonance imaging (MRI).

Pendrin cDNA and Site-directed Mutagenesis {#s2d}
------------------------------------------

The coding region of pendrin cDNA was amplified by PCR from the cDNA library of human thyroid tissue and subcloned into the pEGFP-N1 vector (Invitrogen, Carlsbad, CA, USA) using the *Xho*I and *Kpn*I restriction sites. The pendrin cDNA sequence was verified by nucleotide sequencing, and was identical to a registered sequence (GenBank NM_000441). Oligonucleotide directed mutagenesis was performed to create constructs of 10 mutant plasmids using the QuikChange® Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, USA), according to the manufacturer's protocol. The cloning and mutagenic primers used in this study are listed in [Table S1](#pone.0049984.s008){ref-type="supplementary-material"}.

Cell Culture and Transient Transfection {#s2e}
---------------------------------------

Human embryonic kidney (HEK) cells were cultured in DMEM solution (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. Constructs of pendrin and its mutated plasmids were introduced to the cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The amount of DNA used per 35-mm dish was 4 µg, mixed with 10-µl lipofectamine. For radioisotope uptake experiments, the cells were passaged into 24-well plates 24-h before transfection, at 2×10^5^ cells per well. Cells were quantified using a hemocytometer (Fisher Scientific Inc., Pittsburgh, PA). The quantity of DNA used per well was 0.8 µg, added to 1.6 µl lipofectamine. Fluorescence microscopy was used to evaluate membrane targeting during cell-selection experiments.

Transport Function Assessment {#s2f}
-----------------------------

Conventional radioisotope techniques were used to measure transport functions from HEK cells transfected with plasmids encoding for pendrin and its mutated products, as described in previous studies [@pone.0049984-Bai1]--[@pone.0049984-Tan1]. Pendrin cDNA- and pEGFP-transfected cells were used as the positive and negative controls, respectively. To improve sensitivity, we measured transport function only from those cells that were positively transfected. Fluorescence-based flow cytometry was used for cell sorting. Cells with a fluorescence intensity 4--200 times greater than non-fluorescent cells were selected. In total, 600,000 events (cells) were collected for each sample. To measure \[^14^C\] formate uptake, sorted cells in the 24-well culture cluster were first incubated for 30 min in a solution containing 130 mM NaCl, 20 mM HEPES, 5 mM KCl, 5 mM glucose, 2 mM CaCl~2~ and 1 mM MgCl~2~ (pH 7.3 and 305 Osm/L). Cells were then incubated at RT for 12 min in a solution containing 140 mM K-gluconate, 20 mM HEPES and 5 mM glucose (pH 7.3 and 305 Osm/L). \[^14^C\] formate (Moravek Biochemicals, Inc., Brea, CA) was added to this solution at a concentration of 20 µM. Cells were then washed three times with cold K-gluconate solution without \[^14^C\] formate, lysed with 200 µl 0.5 M NaOH, and neutralized with 0.5 M HCl. The lysate was used for liquid scintillation counting to determine the \[^14^C\] formate uptake. In each run, three wells were assayed for each plasmid, and the experiments were repeated three times independently. Therefore, the data in each group represented a sample size (*n*) of 3×3 = 9 trials for each plasmid and control. Student's *t*-test was used for statistical analysis.

Results {#s3}
=======

By sequencing exons 8, 10, and 19 of *SLC26A4* in 2352 patients, we identified 342 patients with mutations or variants, of which 116 were homozygotes and 226 were heterozygotes. For the 226 patients with monoallelic mutations or variants in exons 8, 10, or 19 of *SLC26A4*, 132 were verified as compound heterozygotes by the subsequent whole ORF analysis, and the other 94 were verified as heterozygotes. The total variant detection rate was 14.54% (342/2352), including a homozygous mutation detection rate of 4.93% (116/2352), a compound heterozygous mutation detection rate of 5.44% (128/2352), and a monoallelic mutation detection rate of 4.17% (98/2352). For patients of Han ethnicity, accounting for 80.52% of our sample, the total variant detection rate, homozygous mutation detection rate, compound heterozygous mutation detection rate and monoallelic mutation detection rates were 16.55% (315/1903), 5.68% (108/1903), 6.46% (123/1903) and 4.41% (84/1903), respectively. Eighty-six types of variants in *SLC26A4* were found, including 7 nonsense variants, 13 frameshift variants, 48 missense variants, 5 splicing site variants, 6 silent variants, 1 untranslated region (UTR) variant and 6 intron variants ([Table 1](#pone-0049984-t001){ref-type="table"}). The missense variants accounted for 60.76% (48/79, excluding the UTR variant and intron variants) of all the *SLC26A4* variants. Of the 86 variants, 47 were novel, which comprised 4 nonsense variants, 6 frameshift variants, 22 missense variants, 2 splicing site variants, 6 silent variants, 1 UTR variant and 6 intron variants ([Table 2](#pone-0049984-t002){ref-type="table"}).

10.1371/journal.pone.0049984.t001

###### Variants information of *SLC26A4* in Chinese population.

![](pone.0049984.t001){#pone-0049984-t001-1}

  No.             Variants               Amino acid          Exon       Mutant allele frequency   Allele frequency   Number of patients
  ----- ---------------------------- ------------------ -------------- ------------------------- ------------------ --------------------
  1              IVS7-2A\>G                              Spicing site     61.6%(**377**/612)      8.01%(377/4704)           271
  2              c.2168A\>G               p.H723R             19          11.60%(**71**/612)       1.51%(71/4704)            59
  3              c.1174A\>T               p.N392Y             10           2.12%(**13**/612)       0.28%(13/4704)            13
  4              c.1229C\>T               p.T410M             10           1.96%(**12**/612)       0.25%(12/4704)            12
  5              c.2027T\>A               p.L676Q             17           1.47%(**9**/612)        0.19%(9/4704)             9
  6               15+5G\>A                               Spicing site      1.14%(**7**/612)        0.15%(7/4704)             8
  7              c.589G\>A                p.G197R             5            0.98%(**6**/612)        0.13%(6/4704)             6
  8              c.1238A\>G               p.Q413R             10           0.98%(**6**/612)        0.13%(6/4704)             6
  9              c.1826T\>G               p.V609G             17           0.82%(**5**/612)        0.11%(5/4704)             5
  10             c.281C\>T                 p.T94I             3            0.65%(**4**/612)        0.08%(4/4704)             4
  11             c.1226G\>A               p.R409H             10           0.65%(**4**/612)        0.08%(4/4704)             4
  12             c.1336C\>T               p.Q446X             11           0.49%(**3**/612)        0.06%(3/4704)             3
  13             c.1548insC             FS517,p.526X          14           0.49%(**3**/612)        0.06%(3/4704)             3
  14             c.1975G\>C               p.V659L             17           0.33%(**2**/612)        0.11%(5/4704)             2
  15             c.259G\>T                 p.D87Y             3            0.33%(**2**/612)        0.04%(2/4704)             2
  16             c.279T\>A                 p.S93R             3            0.33%(**2**/612)        0.04%(2/4704)             2
  17             c.665G\>T                p.G222V             6            0.33%(**2**/612)        0.04%(2/4704)             2
  18             c.1079C\>T               p.A360V             9            0.33%(**2**/612)        0.04%(2/4704)             2
  19         c.1181_1183delTCT           p.S394del            10           0.33%(**2**/612)        0.04%(2/4704)             2
  20             c.1225C\>T               p.R409C             10           0.33%(**2**/612)        0.04%(2/4704)             2
  21          c.1299_1300insC           FS434,p.467X          11           0.33%(**2**/612)        0.04%(2/4704)             2
  22          c.1339_1340delA           FS447,p.454X          11           0.33%(**2**/612)        0.04%(2/4704)             2
  23             c.1343C\>A               p.S448X             12           0.33%(**2**/612)        0.04%(2/4704)             2
  24             c.1595G\>T               p.S532Y             14           0.33%(**2**/612)        0.04%(2/4704)             2
  25          c.1687_1693insA           FS565,p.573X          15           0.33%(**2**/612)        0.04%(2/4704)             2
  27             c.2162C\>T               p.T721M             19           0.33%(**2**/612)        0.04%(2/4704)             2
  28             c.2167C\>G               p.H723D             19           0.33%(**2**/612)        0.04%(2/4704)             2
  26             c.1985G\>A               p.C662Y             17           0.16%(**1**/612)        0.04%(2/4704)             1
  29              c.87G\>C                 p.E29D             2            0.16%(**1**/612)        0.02%(1/4704)             1
  30              c.68C\>A                 p.S23X             2            0.16%(**1**/612)        0.02%(1/4704)             1
  31             c.109G\>T                 p.E37X             2            0.16%(**1**/612)        0.02%(1/4704)             1
  32           c.413_414delT            FS139,p.144X          4            0.16%(**1**/612)        0.02%(1/4704)             1
  33             c.200C\>G                 p.T67S             3            0.16%(**1**/612)        0.02%(1/4704)             1
  34             c.230A\>T                 p.K77I             3            0.16%(**1**/612)        0.02%(1/4704)             1
  35           c.234_235delC             FS79,p.96X           3            0.16%(**1**/612)        0.02%(1/4704)             1
  36             c.249G\>A                 p.W83X             3            0.16%(**1**/612)        0.02%(1/4704)             1
  37            c.43_44insG              FS15,p.86X           2            0.16%(**1**/612)        0.02%(1/4704)             1
  38             IVS4+2T\>C                              Spicing site      0.16%(**1**/612)        0.02%(1/4704)             1
  39             IVS4+7A\>G                              Spicing site      0.16%(**1**/612)        0.02%(1/4704)             1
  40             c.754T\>C                p.S252P             6            0.16%(**1**/612)        0.02%(1/4704)             1
  41             c.757A\>G                p.I253V             6            0.16%(**1**/612)        0.02%(1/4704)             1
  42           c.916_917insG            FS306,p.329X          7            0.16%(**1**/612)        0.02%(1/4704)             1
  43             c.941C\>T                p.S314L             8            0.16%(**1**/612)        0.02%(1/4704)             1
  44          c.1019_1020delT           FS341,p.343X          9            0.16%(**1**/612)        0.02%(1/4704)             1
  45             c.1124A\>G               p.Y375C             9            0.16%(**1**/612)        0.02%(1/4704)             1
  46             c.1173C\>A               p.S391R             10           0.16%(**1**/612)        0.02%(1/4704)             1
  47             c.1240G\>A               p.E414K             10           0.16%(**1**/612)        0.02%(1/4704)             1
  48             c.1245C\>A               p.S415R             10           0.16%(**1**/612)        0.02%(1/4704)             1
  49             c.1262A\>C               p.Q421P             10           0.16%(**1**/612)        0.02%(1/4704)             1
  50             c.1327G\>C               p.E443Q             11           0.16%(**1**/612)        0.02%(1/4704)             1
  51             c.1334T\>G               p.L445W             11           0.16%(**1**/612)        0.02%(1/4704)             1
  52             c.1409G\>A               p.R470H             12           0.16%(**1**/612)        0.02%(1/4704)             1
  53             c.1472T\>C               p.I491T             13           0.16%(**1**/612)        0.02%(1/4704)             1
  54             c.1517T\>G               p.L506R             13           0.16%(**1**/612)        0.02%(1/4704)             1
  55             c.1520delT               p.L597X             13           0.16%(**1**/612)        0.02%(1/4704)             1
  56            IVS13+5G\>A                              Spicing site      0.16%(**1**/612)        0.02%(1/4704)             1
  57             c.1586T\>G               p.I529S             14           0.16%(**1**/612)        0.02%(1/4704)             1
  58             c.1594A\>C               p.S532R             14           0.16%(**1**/612)        0.02%(1/4704)             1
  59          c.1645_1646insA           FS549,p.563X          15           0.16%(**1**/612)        0.02%(1/4704)             1
  60             c.1667A\>G               p.Y556C             15           0.16%(**1**/612)        0.02%(1/4704)             1
  61             c.1678G\>A               p.D560H             15           0.16%(**1**/612)        0.02%(1/4704)             1
  62         c.1733_1735delATA        p.N579del.p.780X        16           0.16%(**1**/612)        0.02%(1/4704)             1
  63             c.1790T\>C               p.L597S             16           0.16%(**1**/612)        0.02%(1/4704)             1
  64             c.1979T\>G               p.L660R             17           0.16%(**1**/612)        0.02%(1/4704)             1
  65             c.1988G\>A               p.G663E             17           0.16%(**1**/612)        0.02%(1/4704)             1
  66             c.1991C\>T               p.A664V             17           0.16%(**1**/612)        0.02%(1/4704)             1
  67             c.1897G\>A               p.E633K             17           0.16%(**1**/612)        0.02%(1/4704)             1
  68             c.1993A\>G               p.I665V             17           0.16%(**1**/612)        0.02%(1/4704)             1
  69             c.1983C\>A               p.D661E             17           0.16%(**1**/612)        0.02%(1/4704)             1
  70             c.2044G\>T               p.E682X             18           0.16%(**1**/612)        0.02%(1/4704)             1
  71             c.2228T\>C               p.L743X             19           0.16%(**1**/612)        0.02%(1/4704)             1
  72             c.2326C\>G               p.R776G             21           0.16%(**1**/612)        0.02%(1/4704)             1
  73             c.225C\>G                 p.L75L             3              0.49%(3/612)          0.06%(3/4704)             3
  74             c.678T\>C                p.A226A             6              0.16%(1/612)          0.02%(1/4704)             1
  75             c.1905G\>A               p.E635E             17             0.33%(2/612)          0.04%(2/4704)             2
  76             c.2205T\>G               p.S735S             19             0.16%(1/612)          0.02%(1/4704)             1
  77             c.2283A\>G               p.T761T             20             0.16%(1/612)          0.02%(1/4704)             1
  78            2343+69 C\>A                                5′UTR          0.16%(**1**/612)        0.02%(1/4704)             1
  79       intron7+(44_46)delACA                           intron7           0.16%(1/612)          0.02%(1/4704)             1
  80     intron9-(28_35)delTTTGTAGG                        intron9           0.16%(1/612)          0.02%(1/4704)             1
  81        Intron12-(7_13)insT                            Intron12        0.16%(**1**/612)        0.02%(1/4704)             1
  82         Intron18-56delCAAA                            Intron18          0.82%(5/612)          0.11%(5/4704)             5
  83          intron19-25T\>A                              intron19          0.49%(3/612)          0.06%(3/4704)             3
  84          intron4-12T\>A\*                             intron4                                                           0
  85            c.2217A\>G\*              p.Q739Q             19                                                             0
  86            c.2176A\>G\*              p.I726V             19                                                             0

Notes:Variants No.1 to 83 were found in deaf patients.Variants No.84 and 86 labeled with \* were carried by hearing normal controls;Mutational allele frequency: the number of mutant alleles/the number of total mutant alleles;FS:frameshift.

10.1371/journal.pone.0049984.t002

###### Novel *SLC26A4* variants found in Chinese hearing loss population.

![](pone.0049984.t002){#pone-0049984-t002-2}

  No.                                      Variants              Exon           Amino Acid         TM Domain
  ------------------------------ ---------------------------- ---------- ------------------------ -----------
  Variants in exons                                                                               
  1                                      c.43_44insG              2          FS 15,stop at 86         NH2
  2                                        c.68C\>A               2               p.S23X              NH2
  3                                        c.87G\>C               2               p.E29D              NH2
  4                                     c.234_235delC             3          FS79,stop at 96          NH2
  5                                       c.249G\>A               3               p.W83X              NH2
  6                                       c.279T\>A               3               p.S93R              NH2
  7                                       c.665G\>T               6              p.G222V              TM5
  8                                       c.757A\>G               6              p.I253V           EC LOOP 3
  9                                       c.941C\>T               8              p.S314L              TM7
  10                                   c.1019_1020delT            9         FS 341,stop at 343     EC LOOP 4
  11                                      c.1124A\>G              9              p.Y375C           IC LOOP 4
  12                                      c.1240G\>A              10             p.E414K           EC LOOP 5
  13                                      c.1245C\>A              10             p.S415R           EC LOOP 5
  14                                   c.1299_1300insC            11        FS 434,stop at 467       TM10
  15                                      c.1327G\>C              11             p.E443Q           IC LOOP 5
  16                                      c.1409G\>A              12             p.R470H           EC LOOP6
  17                                      c.1472T\>C              13             p.I491T             TM12
  18                                      c.1517T\>G              13             p.L506R             COOH
  19                                      c.1595G\>T              14             p.S532I             COOH
  20                                   c.1645_1646insA            15        FS 549,stop at 563       COOH
  21                                      c.1678G\>A              15             p.D560H             COOH
  22                                  c.1733_1735delATA           16      N579 lost, stop at 780     COOH
  23                                      c.1897G\>A              17             p.E633K             COOH
  24                                      c.1979T\>G              17             p.L660R             COOH
  25                                      c.1983C\>A              17             p.D661E             COOH
  26                                      c.1985G\>A              17             p.C662Y             COOH
  27                                      c.1988G\>A              17             p.G663E             COOH
  28                                      c.1993A\>G              17             p.I665V             COOH
  29                                      c.2044G\>T              18             p.E682X             COOH
  30                                      c.2176A\>G              19             p.I726V             COOH
  31                                      c.2228T\>A              19             p.L743X             COOH
  32                                      c.2326C\>G              21             p.R776G             COOH
  **Variants in spicing site**                                                                    
  33                                IVS4+2T\>C (415+2T\>C)     intron4         Spicing site       
  34                               IVS13+5G\>A (1544+5G\>A)    intron13        Spicing site       
  **Variant in UTR**                                                                              
  35                                     2343+69C\>A              21                              
  **Silent variants**                                                                             
  36                                      c.225C\>G               3               p.L75L              NH2
  37                                      c.678T\>C               6              p.A226A              TM5
  38                                      c.1905G\>A              17             p.E635E             COOH
  39                                      c.2205T\>G              19             p.S735S             COOH
  40                                      c.2217A\>G              19             p.Q739Q             COOH
  41                                      c.2283A\>G              20             p.T761T             COOH
  **Variants in introns**                                                                         
  42                                    intron4-12T\>A         intron4                            
  43                                intron7+(44_46delACA)      intron7                            
  44                              intron9-(28_35)delTTTGTAGG   intron9                            
  45                                 intron 12-(7_13)insT      intron12                           
  46                               intron18-(53_56)delCAAA     intron18                           
  47                                   intron19-25T\>A         intron19                           

FS:frameshift;X:stop codon;del:delete.

The mutational spectrum of *SLC26A4* differed among the various ethnicities. IVS7-2A\>G was the most frequent hot-spot mutation in Han, Hui, Mongolian and minorities in the Southwest region, with an allele frequency of 8.01% (377/4704) and a mutant allele frequency of 61.6% (377/612). p.H723R was the second-most frequent hot-spot mutation in Han, Hui, and Mongolian ethnicities with an allele frequency of 1.51% (71/4704) and a mutant allele frequency of 11.6% (71/612). In contrast, neither IVS7-2A\>G nor p.H723R were found in the Tibetan and Uygur patients.

The mutation detection rates were distinct in the hearing loss populations of different ethnicities, with the highest detection rate in the Han population (16.55%), followed by the Hui population (13.48%; homozygous mutation detection rate: 4.49%, compound heterozygous mutation detection rate: 3.37% and monoallelic mutation detection rate: 5.62%) and the Mongolian population (12.12%; homozygous mutation detection rate: 6.06%, compound heterozygous mutation detection rate: 0 and monoallelic mutation detection rate: 6.06%). In contrast, the mutation detection rate in the Tibetan population, and minorities in the Southwest region and Uygur, were low at 4.2, 2.4 and 1.45%, respectively.

The *SLC26A4* mutation detection rates differed geographically in China. Henan province ranked first with a detection rate of 31.58%. Detection rates in Gansu, Heibei, Hubei, Shaanxi and Heilongjiang province were 26.32, 25, 18.75, 18.37 and 16.67%, respectively. The *SLC26A4* mutation detection rate in Guangxi province, the Tibet Autonomous Region and Guizhou province were the lowest at 3.3, 5.08 and 5.4%, respectively. In Guangxi province, no biallelic *SLC26A4* mutations were found in the 90 patients enrolled. In the Tibet Autonomous Region, biallelic *SLC26A4* mutations were detected only in patients of Han ethnicity. The geographic distribution and the proportion of patients carrying two *SLC26A4* mutant alleles in each region are shown in [Figure S1](#pone.0049984.s001){ref-type="supplementary-material"}. Our results revealed that the incidence of EVA varied geographically in Mainland China. Surprisingly, we found that no Tibetan patients with EVA living in the Tibet plateau were diagnosed either by *SLC26A4* genetic testing or by high resolute temporal bone CT scan.

Four IVS7-2A\>G heterozygotes, one missense c.2176A\>G (p.I726V) heterozygote, one silent variant c.2217A\>G (p.Q739Q), one silent variant c.225C\>G (p.L75L) and one intron variant (intron4-12T\>A) were found in the control group. Although this control population may be too small to reach a final conclusion, the carrier rate of *SLC26A4* mutations in China is estimated to be about 2.5%. Polymorphisms in *SLC26A4* appear to be rare in the general population in comparison to those in *GJB2* [@pone.0049984-Yuan1].

Phenotype {#s3a}
---------

Of the 342 hearing loss patients with mutations or variants in *SLC26A4*, 320 were examined by temporal CT scan or MRI. The follow-up of the remaining 22 patients (4 with biallelic mutations and 18 with monoallelic mutations) failed. All patients (240/240) with biallelic mutations or biallelic variants (not including silent variants) and 23.75% (19/80) of those with monoallelic mutations or variants in the ORF of *SLC26A4* were confirmed to have EVA by temporal bone CT scan or MRI ([Figure S2](#pone.0049984.s002){ref-type="supplementary-material"}). All patients diagnosed with EVA in our study showed moderate to profound bilateral sensorineural hearing impairment on audiograms ([Figure S3](#pone.0049984.s003){ref-type="supplementary-material"}). Because none of our patients showed goiter upon physical examination, the perchlorate discharge test was not performed in our study.

Functional Study on the 10 SLC26A4 Variants {#s3b}
-------------------------------------------

We chose 10 *SLC26A4* variants for functional study using the heterologous expression system. Of these, c.279T\>A (p.S93R), c.665G\>T (p.G222V), c.941C\>T (p.S314L), c.1517T\>G (p.L506R), c.1985G\>A (p.C662Y), and c.2326C\>G (p.R776G) have not been reported before. c.259G\>T (p.D87Y), c.1079C\>T (p.A360V), c.1225C\>T (p.R409C) and c.1991C\>T (p.A664V) have only been detected in ethnic Chinese [@pone.0049984-Lai1]--[@pone.0049984-Huang1]. Patients with the above 10 variants also carried an identified mutation, such as IVS7-2 A\>G or c.2168 A\>G (p.H723R) or c.1174 A\>T (p.N392Y) on the other allele, and all were diagnosed with EVA by CT scan. The molecular epidemiological information and sift prediction of the pathogenicity of the ten variants are summarized in [Table 3](#pone-0049984-t003){ref-type="table"}. The sift prediction of seven variants (p.D87Y, p.S93R, p.G222V, p.S314L, p.R409C, p.L506R, p.C662Y) was damaging, while the other three (p.A360V, p.A664V and p.R776G) was tolerated. All of the missense SLC26A4 variants, except p.L506R, p.C662Y and p.A664V, affect amino acids located in highly conserved regions of the *SLC26A4* orthologs. However, L506, C662 and A664 are located in conserved regions of most of the *SLC26A4* orthologs ([Figure S4](#pone.0049984.s004){ref-type="supplementary-material"}). None of the 10 *SLC26A4* variants was found in the normal-hearing control group.

10.1371/journal.pone.0049984.t003

###### Molecular epidemiological information of ten *SLC26A4* variants in 2352 unrelated NSHL patients.

![](pone.0049984.t003){#pone-0049984-t003-3}

  No     Variants    Exon   Amino Acid   Phenotype   Sift Prediction   Location in Pendrin   Variant frequency   Allele Frequency
  ---- ------------ ------ ------------ ----------- ----------------- --------------------- ------------------- ------------------
  1     c.259G\>T     3       p.D87Y        EVA         DAMAGING               NH2             0.33%(2/612)       0.04%(2/4704)
  2     c.279T\>A     3       p.S93R        EVA         DAMAGING               TM1             0.33%(2/612)       0.04%(2/4704)
  3     c.665G\>T     6      p.G222V        EVA         DAMAGING               TM5             0.33%(2/612)       0.04%(2/4704)
  4     c.941C\>T     8      p.S314L        EVA         DAMAGING               TM7             0.16%(1/612)       0.02%(1/4704)
  5     c.1079C\>T    9      p.A360V        EVA         TOLERATED              TM8             0.16%(1/612)       0.02%(1/4704)
  6     c.1225C\>T    10     p.R409C        EVA         DAMAGING            ECLOOP 5           0.33%(2/612)       0.04%(2/4704)
  7     c.1517T\>G    13     p.L506R        EVA         DAMAGING              COOH             0.16%(1/612)       0.02%(1/4704)
  8     c.1985G\>A    17     p.C662Y        EVA         DAMAGING              COOH             0.16%(1/612)       0.04%(2/4704)
  9     c.1991C\>T    17     p.A664V        EVA         TOLERATED             COOH             0.16%(1/612)       0.02%(1/4704)
  10    c.2326C\>G    21     p.R776G        EVA         TOLERATED             COOH             0.16%(1/612)       0.02%(1/4704)

Membrane targeting is essential for the functional expression of a membrane-bound protein. We questioned whether these mutations could alter the folding of the 10 variants, which could result in reduced or loss of membrane expression. It has been demonstrated that pendrin shows robust membrane-targeted expression in HEK 293 cells. To determine whether these 10 variants were expressed in the membrane, we used confocal microscopy to examine the expression of EGFP and a membrane-based dye, di-8-amino-naphthylethenyl-pyridinium (di-8-ANEPPS) in HEK cells after transfecting the cells with plasmids containing one of the 10 variants tagged by EGFP. Di-8-ANEPPS is a member of the ANEP (aminoaphthyl ethenyl pyridinium) class of membrane potential dyes. Co-localization of EGFP expression and the di-8-ANEPPS dye in the membrane would suggest proper membrane targeting of the proteins [@pone.0049984-Tang1]. [Figure S5](#pone.0049984.s005){ref-type="supplementary-material"} shows representative images of membrane expression patterns of the 10 mutant pendrins. For comparison, membrane expression of the normal pendrin protein is also presented. Although it appeared that p.D87Y, p.S93R, p.G222V, p.R409C, p.L506R, p.C662Y, p.A664V and p.R776G all reached the plasma membrane, their expression levels were reduced when compared to normal pendrin. Other mutant pendrins (p.S314L, p.A360V, p.R409C, p.L506R, p.C662Y and p.R776G) were also localized to the cytosol, indicating retention in the intracellular region.

It has been suggested that the defect in Cl−/HCO~3~- exchange activities at the apical membrane of inner ear epithelial cells is the key factor that causes EVA and deafness [@pone.0049984-Pera1]. We evaluated the transport activity of each mutant pendrin and compared it with that of WT-pendrin. A conventional radioisotope technique was used to measure \[^14^C\] formate uptake after sorting of EGFP-positive cells by fluorescence-based flow cytometry. Cells transfected with EGFP-vector only were used as a negative control. As shown in [Figure S6](#pone.0049984.s006){ref-type="supplementary-material"}, all mutant pendrins showed significantly decreased transport function compared to that of normal pendrin (*P*\<0.01). Pfarr *et al*. reported that the p.R776C mutation does not compromise transporter activity [@pone.0049984-Pfarr1]. We showed here that the transporter activity of p.R776G was significantly reduced, although the reduction was less dramatic than in other variants.

Discussion {#s4}
==========

Mutations in *SLC26A4*, which encodes pendrin, are a common cause of deafness, and are responsible for both syndromic and non-syndromic hearing loss. The mutation spectrum of *SLC26A4* varies widely among ethnic groups [@pone.0049984-Chang1]. In addition, the prevalence of mutations varies among ethnic groups. Campbell et al. reported p.T416P and IVS8+1G\>A as the two most frequent mutations in northern European populations [@pone.0049984-Campbell1], whereas Blons et al. reported a completely different mutation spectrum that was extremely heterogeneous [@pone.0049984-Blons1]. In a Japanese population, p.H723R accounted for 53% of the mutant alleles, and in a Korean population, p.H723R and the IVS7-2A\>G mutation were the most prevalent, accounting for 45.5% of patients with PS or EVA [@pone.0049984-Park1], [@pone.0049984-Tsukamoto1]. In China, the IVS7-2A\>G mutation was the most common form, accounting for 57.63% of the mutant alleles [@pone.0049984-Wang1].

All of the above studies focused on patients with EVA or Pendred syndrome. Few large-scale molecular epidemiological surveys on the *SLC26A4* gene in hearing loss populations have been reported. Previous studies verified that about 90% of Chinese patients with EVA carried at least one allelic mutation in exons 8, 19 or 10 of *SLC26A4* [@pone.0049984-Wang1], [@pone.0049984-Dai1], [@pone.0049984-YuanYY1]. Because *SLC26A4* is a large gene with 20 exons, hot-spot region screening in a molecular epidemiological survey is an economical method. *SLC26A4* mutations were detected in nearly 15% of 2352 non-syndromic Chinese hearing impairment patients, with IVS7-2A\>G being the most prevalent. By screening the above three exons of *SLC26A4*, we verified that the ratio of EVA in the Chinese deaf population was at least 11%, and that in the Han ethnicity reached at least 13%. Of our patients with EVA, 23.75% carried only one missense mutation. Whether the missense mutation causes a dominant negative effect and/or specifies a different phenotype is not clear. It is possible that the second mutant allele has not yet been identified due to the location of mutations deep in introns or promoter regions that were not sequenced, intragenic exon deletions, or the involvement of mutations in genes other than *SLC26A4*, such as *FOXI* and *KCNJ10* (i.e., digenic synergistic mutations). However, none of our patients with one *SLC26A4* missense mutation carried any of the reported *FOXI* or *KCNJ10* mutations.

We found that different ethnicities that originated from various regions of China showed distinct *SLC26A4* mutational spectra and detection rates, which may be explained by the genetic heterogeneity in various ethnicities. For example, the mutation detection rates in the Tibetan population and minorities in the Southwest region and Uygur populations were significantly lower than that in the Han, Hui and Mongolian populations. Although IVS7-2A\>G and p.H723R were hot mutations in Han, Hui and Mongolian patients, they were not found in the Tibetan and Uygur patients. Our results also revealed that the *SLC26A4* detection rate and incidence of EVA varied geographically. The incidence of inner ear malformation in the Tibetans living in the Tibet plateau was almost as high as that in Chinese Han patients, but the types of malformation in the Tibetan population differed greatly [@pone.0049984-Yuan2]. The most-common inner ear deformity, EVA, is rare in the Chinese Tibetan hearing-loss population. Hypoxia may be one of the causes of development of inner ear deformity, but further studies are required to determine the genetic etiology of hearing loss in Tibetan patients. We also found that the detection rate of another common gene, *GJB2*, was significantly lower in Guangxi province (6.05%) than the average rate in China (21.01%) [@pone.0049984-Dai2]. These results may be explained by the influence of regional or environmental on the etiology of hearing loss in Guangxi.

A striking achievement of this study is the establishment of a new strategy for detecting *SLC26A4* mutations prior to temporal bone CT scan for identifying patients with EVA. In China, the cost of a temporal CT scan is 200 to 300 RMB (approximately 3 days' salary of an average Chinese). Because of the relatively high cost, it is not possible to perform a CT scan in every hearing loss patient for diagnosis of EVA. Because 97.9% of Chinese patients with EVA carry an *SLC26A4* mutation [@pone.0049984-Wang1], *SLC26A4* mutations in hearing loss patients indicate a high possibility of EVA. This model has the unique advantage of identifying patients with EVA in an epidemiologic study in large-scale deaf populations.

The discovery of 47 novel variants enriches the mutational spectrum of *SLC26A4*. Functional tests of mutated pendrin allelic variants found in patients with Pendred syndrome or non-syndromic EVA revealed that the pathology is linked to a reduction or a loss of function in the ion transport activity of pendrin [@pone.0049984-Taylor1], [@pone.0049984-Yoon1]. Subcellular localization studies revealed that the mutated proteins are often retained in subcellular compartments and are unable to reach the plasma membrane [@pone.0049984-RotmanPikielny1], [@pone.0049984-Dai3]. These mutations most likely cause protein misfolding, followed by impaired trafficking and subsequent degradation. Furthermore, the transport function of mutated proteins that do reach the membrane is impaired [@pone.0049984-Taylor1], [@pone.0049984-Choi1], [@pone.0049984-Dossena1]. Besides clinical and radiological assessments, the functional evaluation of pendrin mutations is essential for correct diagnosis of Pendred syndrome and non-syndromic EVA [@pone.0049984-Fugazzola1]. Indeed, the clinical condition of pseudo-Pendred syndromes [@pone.0049984-Fugazzola2]--[@pone.0049984-Davis1] and the high incidence of functional pendrin polymorphisms in some populations [@pone.0049984-Pera1] could lead to an incorrect assignment of the pathological conditions in cases where proper functional characterizations are not possible. Whereas a broad spectrum of mutations is found in Caucasian populations, and Israeli and Palestinian populations have been functionally characterized [@pone.0049984-Dossena2], [@pone.0049984-Dossena3], little about the variants that occur in Chinese is known.

We used confocal microscopy and radioisotope techniques to examine the membrane expression and transporter function of 10 mutant proteins in human embryonic kidney cells. We showed that all 10 mutations resulted in a significant reduction in membrane expression of the proteins. Measurement using a radioisotope technique showed that their transport activity was significantly reduced. Our results suggest that the pathogenesis underlying the hearing loss associated with these mutations is the result of reduced membrane expression and decreased transport capability of the proteins.

Pera et al. [@pone.0049984-Pera1] suggested that certain biochemical parameters explained some functional impairment. For example, transport function was impaired if an amino acid bearing a fixed charge was missing or introduced (i.e., aspartic acid (D) with fixed negative charge (K) or glutamic acid (EK), lysine (K) with positive fixed charge (C) or arginine (RC), and histidine (HC) with the positive charge of histidine, depending on the pH). Furthermore, the loss or inclusion of a proline (P; proline acts as a structural disruptor of regular secondary structures such as α-helices or β-sheets) in the *SLC26A4* sequence is detrimental to its transport function. However, Pfarr et al. [@pone.0049984-Pfarr1] described p.R776C as an exception, with an arginine located on the extreme C-terminus of *SLC26A4* (a 780 amino acid protein). It is thought that the N- and C-termini of a protein are not structural and the mutations occurring in these areas probably have little or no functional impact [@pone.0049984-Pera1]. However, with regard to the EVA phenotype, the p.R776G mutation in Chinese was found at very low allele frequency in the control group.

In conclusion, we provide an overview of the molecular epidemiological status of *SLC26A4* in China. We showed that the prevalence of EVA in the Chinese deaf population was at least 11%, which reached at least 13% in the Han majority population. The mutational spectrum and mutation detection rate of *SLC26A4* are distinct among both ethnicities and regions of mainland China. Our results suggest that the pathogenesis underlying hearing loss in patients with EVA is the result of reduced membrane expression and the decreased transport activity of the mutant pendrins. The functional assessment procedure can be applied to genetic diagnosis of EVA patients and prenatal diagnosis for their families. These findings are valuable for genetic counseling and risk assessment for families with EVA in China.

Supporting Information {#s5}
======================

###### 

**Geographic distribution and the proportion of patients carrying two** ***SLC26A4*** **mutant alleles in each region studied.** NE: not examined

(TIF)

###### 

Click here for additional data file.

###### 

**Examples of CT and MRI images of normal children and children with** ***SLC26A4*** **mutations.** A: CT of temporal bone of a normal child. Arrows show the normal vestibular aquaduct. B: CT of a patient with EVA. Arrows mark the enlarged vestibular aquaduct. C: MRI of child with normal inner ear. Arrows indicate the normal endolymphatic sac. D: MRI of a patient with EVA. Arrows mark the hydrop of endolymphatic sac.

(TIF)

###### 

Click here for additional data file.

###### 

**Representative pure-tone audiograms of children with** ***SLC26A4*** **mutations.** A: c.259G\>T/c.2168A\>G. B: c.941C\>T/c.1174A\>G. C: c.1517T\>G/IVS7-2A\>G. D: c.1991C\>T/IVS7-2A\>G

(TIF)

###### 

Click here for additional data file.

###### 

**Protein sequences of 13 SLC26A4 orthologs, including: (1) Homo sapiens (NP_000432.1), (2) Nomascus leucogenys (XP_003268184.1), (3) Pan troglodytes (XP_519308.2), (4) Macaca mulatta (XP_001094049.1), (5) Callithrix jacchus (XP_002751785.1), (6) Sus scrofa (XP_003357559.1), (7) Canis lupus familiaris (XP_540382.3), (8) Rattus norvegicus (NP_062087.1), (9) Mus musculus (NP_035997.1), (10) Oryctolagus cuniculus (XP_002712085.1), (11) Loxodonta africana (XP_003407255.1), (12) Xenopus (Silurana) tropicalis (NP_001107135.1), and (13) Monodelphis domestica (XP_001363598.1).**

(TIF)

###### 

Click here for additional data file.

###### 

**Heterologous expression of wild-type and mutant pendrins.** HEK cells were transfected with each plasmid of the 10 variants tagged by EGFP. A membrane-based dye (orange color), di-8-ANEPPS, was also added in the solution before confocal microscopy. Co-localization of EGFP expression and the di-8-ANEPPS dye in the membrane would suggest proper membrane targeting of the proteins.

(TIF)

###### 

Click here for additional data file.

###### 

**Transport activity of wild-type pendrin and 10 mutant pendrins.**

(TIF)

###### 

Click here for additional data file.

###### 

**SLC26A4 Site-Directed Mutagenesis Primers.** The mRNA from normal human adenoid specimens was extracted, and cDNA was synthesized. PCR was done to catch the target gene. Primers were as follows: *Xho*I -F:5′- CCGCTCGAGATGGCAGCGCCAGGCGGCAG -3′ KpnI -R:5′- GGGGTACCGTGGATGCAAGTGTACGCATAG -3′ *Xho*I -F contains protective base and XhoI restriction sites, its 5 \'end partial sequence for PCR amplify target gene. KpnI -R contains protective base and KpnI restriction sites,its 3 \'end partial sequence for PCR amplify target gene. The entire ORF of the human SLC26A4 gene was cloned into the expression vector pEGFP-N1 (Invitrogen, Carlsbad, CA, USA). The point mutation-specific primers were synthesized as shown in [Table S1](#pone.0049984.s008){ref-type="supplementary-material"}.

(DOCX)

###### 

Click here for additional data file.

###### 

**SLC26A4 Site-Directed Mutation Primers.**

(DOCX)

###### 

Click here for additional data file.
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